Palvella Therapeutics
PVLA
130.59
+2.59
+2.02%
Palvella Therapeutics
US · PVLA
#2822 by market cap
Listed 1970
130.59
+2.59
+2.02%
Live - 5344 symbols - heartbeat 152s ago
· 2026-10-08 04:00
Pre-market
131.00
+0.31%
After-hours
130.70
+0.08%
Overnight
130.05
-0.41%
- Market cap
- 1.88B
- P/E (TTM)i
- -26.93
- P/Bi
- 8.68
- EPSi
- -3.71
- Div yieldi
- 0.00%
- 52W posi
- 68%
Reader sentiment
Are you bullish or bearish on PVLA?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 4 years
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 4.16M | 3.08M | 5.94M | 15.76M |
| Research & development | 13.88M | 8.79M | 8.15M | 22.84M |
| Operating profit | -18.04M | -11.87M | -14.10M | -38.60M |
| Pretax profit | -28.58M | 18.69M | -17.43M | -41.72M |
| Tax | -1.03M | 0 | 0 | 0 |
| Net profit | -27.55M | 18.69M | -17.43M | -41.72M |
| Basic EPS | -2 | 2 | -8 | -4 |
| Diluted EPS | -2.46 | 1.60 | -7.83 | -3.71 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 3.80M | 4.13M | 3.65M | 4.18M | 5.52M | 8.93M |
| Research & development | 4.07M | 5.12M | 6.53M | 7.12M | 9.33M | 12.47M |
| Operating profit | -7.87M | -9.25M | -10.18M | -11.30M | -14.86M | -21.41M |
| Pretax profit | -8.19M | -9.47M | -11.35M | -12.71M | -15.77M | -21.87M |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -8.19M | -9.47M | -11.35M | -12.71M | -15.77M | -21.87M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -2 |
| Diluted EPS | -0.74 | -0.86 | -1.03 | -1.08 | -1.20 | -1.52 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | 16.52M | 7.55M | 88.23M | 58.99M |
| Cash & ST investments | 16.05M | 7.35M | 83.60M | 57.98M |
| Inventory | -- | -- | -- | -- |
| Total assets | 16.52M | 7.55M | 88.23M | 59.56M |
| Total current liabilities | 5.78M | 2.36M | 12.04M | 11.34M |
| Short-term debt | -- | -- | -- | 202.00K |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | 39,698,000.00 | 11,428,000.00 | 25,627,000.00 | 31,576,000.00 |
| Total equity | -23.17M | -3.88M | 62.61M | 27.98M |
| Retained earnings | -94.99M | -76.30M | -93.74M | -135.45M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 79.44M | 73.75M | 66.94M | 58.99M | 263.23M | 253.03M |
| Cash & ST investments | 75.63M | 70.43M | 63.57M | 57.98M | 261.85M | 250.58M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 79.44M | 73.75M | 66.94M | 59.56M | 263.76M | 253.51M |
| Total current liabilities | 8.98M | 9.62M | 10.31M | 11.34M | 9.12M | 11.95M |
| Short-term debt | -- | -- | -- | 202.00K | 209.00K | 217.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 23,862,000.00 | 25,967,000.00 | 28,255,000.00 | 31,576,000.00 | 31,446,000.00 | 36,643,000.00 |
| Total equity | 55.58M | 47.78M | 38.68M | 27.98M | 232.31M | 216.87M |
| Retained earnings | -101.92M | -111.39M | -122.74M | -135.45M | -151.22M | -173.09M |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -14.84M | -13.70M | -10.84M | -25.01M |
| Depreciation & amortization | -- | -- | -- | -- |
| Free cash flow | -14.84M | -13.70M | -10.84M | -25.01M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- |
| Ending cash balance | 16.05M | 7.35M | 83.60M | 57.98M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -6.77M | -5.43M | -7.88M | -4.93M | -10.86M | -12.85M |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -6.77M | -5.43M | -7.88M | -4.93M | -10.86M | -12.85M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -- | -- | 230.00M | 0 |
| Ending cash balance | 75.63M | 70.43M | 63.57M | 57.98M | 206.39M | 187.80M |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -92.10 |
| ROA %i | -166.74 | 148.85 | -36.40 | -56.45 |
| ROIC %i | -- | -- | -- | -83.80 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | 2.86 | 3.20 | 7.33 | 5.20 |
| Quick ratioi | 2.78 | 3.11 | 7.14 | 5.11 |
| Debt / assetsi | -- | -- | 0.00 | 1.06 |
| LT debt / equityi | -- | -- | -- | 1.54 |
| Interest coveragei | -- | -- | -3.04 | -6.17 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -58.59 | -83.68 | -92.10 | -34.25 | -46.63 |
| ROA %i | -53.34 | -37.96 | -48.36 | -56.45 | -28.73 | -37.70 |
| ROIC %i | -- | -47.89 | -69.77 | -83.80 | -31.53 | -43.87 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 8.84 | 7.67 | 6.49 | 5.20 | 28.88 | 21.18 |
| Quick ratioi | 8.64 | 7.53 | 6.38 | 5.11 | 28.73 | 20.97 |
| Debt / assetsi | -- | -- | -- | 1.06 | 0.22 | 0.21 |
| LT debt / equityi | -- | -- | -- | 1.54 | 0.16 | 0.15 |
| Interest coveragei | -3.88 | -4.55 | -5.12 | -6.17 | -6.42 | -7.12 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 04:00:14 · For reference only, not investment advice and not tailored to your situation.